TorontoStartsBook a call

Early Cancer Detection: How Revolutionary DNA Blood Tests Are Transforming Cancer Screening

Silicon Scoop · September 1, 2025

Early Cancer Detection: How Revolutionary DNA Blood Tests Are Transforming Cancer Screening https://torontostarts.com/2025/09/01/early-cancer-detection-dna-tests/ Apple -> https://podcasts.apple.com/us/podcast/flowgrammer-podcast/id1804155588 Spotify -> https://open.spotify.com/show/0wv3feR00iaVpE8zn7niNf Flowgrammer.ca -> https://flowgrammer.ca/ AI News and Resources -> https://flowgrammer.ca/resources/ Future-Proof Your Business Now! 🤖 Just like early cancer detection offers a chance for intervention, proactive business automation allows you to address inefficiencies before they impact your bottom line. Don't wait until it's too late! Discover Automation Solutions https://flowgrammer.ca/ Startup Investor Drinks Toronto - https://startupdrinksto.com/ Toronto’s Startup Community - https://torontostarts.com/ Silicon Scoop Silicon Scoop Podcast - https://torontostarts.com/silicon-scoop/ Apple: https://podcasts.apple.com/us/podcast/silicon-scoop/id1758711826 Spotify: https://open.spotify.com/show/5bAzF0MwV6TtLhJAhvHayI YouTube: https://www.youtube.com/playlist?list=PLj4v-RoA7A-gT62vrEYqh1zCv-0Hj-o5J Startup Talk Startup Talk Podcast -> https://torontostarts.com/startup-talk-toronto-startup-podcast/ Apple -> https://podcasts.apple.com/us/podcast/startup-talk/id1763804003 Spotify -> https://open.spotify.com/show/1siJMILILidHAiAsrX2VBU YouTube: https://youtube.com/playlist?list=PLj4v-RoA7A-jxV5FHs5e61oIsuvUJYmT_&si=LYegRe5GYLKNQ7xL

With Craig Major and Jon Irwin

Open audio in your browser
Early Cancer Detection: How Revolutionary DNA Blood Tests Are Transforming Cancer Screening

Early Cancer Detection: How DNA Blood Tests Are Revolutionizing Cancer Screening

Estimated reading time: 12 minutes

Table of contents

Early cancer detection represents one of medicine’s most promising frontiers. It involves identifying cancer before clinical symptoms appear, offering patients the best possible chance for successful treatment.

Revolutionary DNA blood tests are transforming how we approach cancer screening. These innovative liquid biopsy cancer techniques can detect microscopic traces of tumor activity years before traditional methods.

At the heart of this breakthrough lies circulating tumor DNA. These are tiny fragments of DNA shed by tumor cells into the bloodstream. Advanced testing methods can identify these fragments as cancer biomarkers, providing early warning signs of disease development.

This technological advancement promises to change cancer care forever. Early detection could mean the difference between a simple treatment and a complex battle for survival.

The Need for Early Cancer Detection & Advanced DNA Testing Technology

Early cancer diagnosis saves lives. When cancer is caught in its earliest stages, treatment success rates increase dramatically. The five-year survival rate for many cancers exceeds 90% when detected early, compared to just 15-20% for late-stage diagnoses.

DNA blood tests work by detecting tumor-specific DNA fragments circulating in the bloodstream. Unlike traditional screening methods that look for physical tumors, these tests identify molecular evidence of cancer development.

The process of tumor DNA detection relies on advanced sequencing techniques. These methods can find minute traces of cancer DNA among millions of normal DNA fragments. The sensitivity required is extraordinary – like finding a single grain of sand on a beach.

Circulating tumor DNA serves as reliable cancer biomarkers. As tumors grow, they continuously shed DNA into the bloodstream. This creates a detectable molecular signature that sophisticated tests can identify.

The potential for improved cancer screening is remarkable. These tests can identify cancer up to three years before clinical diagnosis. This early warning system could revolutionize patient care and treatment outcomes.

Current screening methods have limitations. Mammograms, colonoscopies, and CT scans can only detect tumors once they reach a certain size. By then, cancer may have already spread to other parts of the body.

DNA-based early cancer detection offers several advantages:

  • Detection before symptoms appear
  • Non-invasive blood draw procedure
  • Potential for regular monitoring
  • Multi-cancer screening capabilities
  • Earlier treatment intervention

The science behind these tests continues advancing rapidly. Researchers are developing more sensitive detection methods and expanding the range of cancers that can be identified through blood analysis.

Future-Proof Your Business Now! 🤖

Just like early cancer detection offers a chance for intervention, proactive business automation allows you to address inefficiencies before they impact your bottom line. Don’t wait until it’s too late!

Discover Automation Solutions

The technology powering early cancer detection represents a quantum leap in medical diagnostics. Two primary methods are leading this revolution: whole-genome sequencing and cell-free DNA fragmentomics.

Whole-genome sequencing scans the entire genome to identify cancer-specific mutations. This technology can detect these mutations even when present at extremely low concentrations in archived blood samples.

Recent research demonstrates the power of this approach. Whole-genome sequencing identified cancer-specific mutations in blood samples collected more than three years prior to diagnosis in select participants. This finding suggests that tumor DNA detection capabilities extend far beyond previous expectations.

The process involves several sophisticated steps:

  • Blood sample collection and processing
  • DNA extraction and amplification
  • Comprehensive genome analysis
  • Mutation identification algorithms
  • Pattern recognition software

This liquid biopsy cancer approach offers unprecedented sensitivity. The technology can identify single nucleotide changes among billions of DNA base pairs. Such precision enables detection of the earliest molecular signs of cancer development.

Cell-Free DNA Fragmentomics Analysis

Cell-free DNA fragmentomics represents another breakthrough in early cancer detection. This technique employs machine learning to analyze DNA fragmentation patterns, distinguishing cancerous fragments from benign ones.

The results are impressive. Multi-cancer early detection tests achieve 87.4% sensitivity and 97.8% specificity using cell-free DNA fragmentomics. These statistics indicate high accuracy in both detecting actual cancers and avoiding false positives.

Machine learning algorithms analyze several key factors:

  • Fragment size distribution patterns
  • Nucleosome positioning signals
  • Tissue-of-origin signatures
  • Methylation patterns
  • Coverage depth variations

The fragmentomics approach leverages the fact that cancer cells process DNA differently than healthy cells. These differences create unique fragmentation signatures that sophisticated algorithms can identify.

Integration of Multiple Technologies

The most promising DNA blood tests combine multiple analytical approaches. By integrating whole-genome sequencing with fragmentomics analysis, researchers achieve higher accuracy rates than either method alone.

This multi-modal approach strengthens cancer biomarkers detection. Different technologies capture different aspects of tumor biology, creating a more comprehensive picture of disease development.

The promise of these technologies extends beyond detection. Early intervention becomes possible before traditional clinical symptoms and imaging findings emerge. This represents a fundamental shift from reactive to proactive cancer care.

Current research focuses on improving sensitivity while maintaining specificity. The goal is developing tests that can reliably detect the earliest stages of cancer development across multiple tumor types simultaneously.

https://flowgrammer.ca/

Breakthrough Research Findings and Clinical Evidence

Cancer DNA Detectable in Blood Years Before Diagnosis

Groundbreaking research has confirmed what scientists long suspected: cancer DNA becomes detectable in blood years before traditional diagnosis methods identify tumors. This discovery represents a paradigm shift in early cancer detection capabilities.

The headline finding demonstrates remarkable potential. Tumor-specific mutations can be detected in blood samples up to three years before diagnosis. This extended detection window opens unprecedented opportunities for early intervention and improved patient outcomes.

Clinical Performance Statistics

Recent studies reveal impressive performance metrics for DNA blood tests. Early detection test sensitivity reaches 87.4%, while specificity achieves 97.8%. These statistics indicate that liquid biopsy cancer tests can reliably identify true positives while minimizing false alarms.

The sensitivity percentage means the test correctly identifies 87.4% of actual cancers present. The specificity rate indicates that 97.8% of negative results are truly cancer-free. These performance levels approach clinical utility standards.

The accuracy continues improving as technology advances and researchers refine testing methods.

Technical Implementation Details

Whole-genome sequencing drives these remarkable results. The technology analyzes entire genetic sequences to identify cancer-specific genomic alterations at extremely low concentrations in archived blood samples.

Cell-free DNA fragmentomics provides complementary detection capabilities. Machine learning algorithms trained on DNA fragmentation patterns distinguish cancer signatures from benign conditions with high accuracy.

The research demonstrates that circulating tumor DNA serves as reliable cancer biomarkers even in early disease stages. Tumor cells continuously shed genetic material into the bloodstream, creating detectable molecular signatures.

Multi-Cancer Detection Capabilities

These tests show promise for detecting multiple cancer types simultaneously. Early cancer diagnosis becomes possible across various organ systems through a single blood draw. This multi-cancer screening approach could revolutionize routine healthcare.

Current research includes several major cancer types:

  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Pancreatic cancer
  • Ovarian cancer
  • Liver cancer
  • Stomach cancer

The ability to screen for multiple cancers addresses a major limitation of current screening programs. Traditional methods typically focus on single cancer types and require different procedures for each screening.

Research continues expanding the list of detectable cancers. The goal is eventually screening for all major cancer types with a single test.

https://pubmed.ncbi.nlm.nih.gov/

Expert Commentary and Future Treatment Implications

Leading Researcher Perspectives

Medical experts are responding to these breakthrough findings with cautious optimism. The research represents significant progress in early cancer detection, but validation remains crucial for clinical implementation.

Yuxuan Wang from Johns Hopkins described the findings as “provocative” while emphasizing the need to validate results in larger populations. This perspective reflects the scientific community’s balanced approach to promising new technologies.

Wang’s commentary highlights important considerations:

  • Sample size limitations in initial studies
  • Need for diverse population validation
  • Importance of reproducible results
  • Clinical utility requirements
  • Cost-effectiveness considerations

William Grady from the Fred Hutchinson Center offers an even more forward-looking perspective. He envisions future precancer elimination therapies while stressing the importance of further validation.

Grady’s vision includes several revolutionary concepts:

  • Therapeutic targeting of precancerous conditions
  • Prevention-focused treatment approaches
  • Molecular-guided intervention strategies
  • Personalized risk assessment protocols
  • Integration with existing screening programs

Transforming Cancer Care Landscape

These research findings promise to change the entire landscape of cancer screening and patient management. The shift from reactive to proactive care could revolutionize oncology practice.

Traditional cancer care follows a detection-to-treatment model. Patients receive treatment after tumors become clinically apparent. This approach often means treating advanced disease with limited options.

DNA blood tests enable a prevention-focused model. Healthcare providers could identify molecular signs of cancer development years before tumors become visible. This early warning system allows for much earlier intervention.

Integration with Routine Healthcare

The potential for integrating advanced DNA blood tests into routine screening processes represents a major healthcare advancement. These tests could become part of regular annual checkups, similar to cholesterol or blood pressure monitoring.

Integration advantages include:

  • Simple blood draw procedure
  • No special patient preparation required
  • Results available within days
  • Multi-cancer screening capability
  • Cost-effective population screening

Healthcare systems worldwide are evaluating how to incorporate these technologies. The challenge involves balancing test sensitivity with healthcare resource allocation.

Personalized Medicine Applications

Early cancer detection through circulating tumor DNA opens new possibilities for personalized medicine. Molecular signatures could guide treatment selection even before tumors develop.

This approach enables:

  • Risk-stratified monitoring protocols
  • Targeted prevention strategies
  • Personalized screening intervals
  • Precision intervention therapies
  • Biomarker-guided care pathways

The integration of DNA blood tests with other diagnostic technologies creates comprehensive patient assessment platforms. Combined with genetic risk factors and lifestyle data, these tests could provide unprecedented insight into cancer risk.

Healthcare System Implications

Widespread adoption of early cancer detection technology could transform healthcare economics. While test costs may be significant, early detection typically reduces overall treatment expenses.

Economic benefits include:

  • Reduced treatment complexity
  • Shorter hospital stays
  • Less invasive procedures
  • Lower medication costs
  • Improved patient productivity

Healthcare policymakers are beginning to evaluate coverage decisions for these emerging technologies. The challenge involves determining appropriate patient populations and testing frequencies.

https://www.fredhutch.org/

Current Limitations and Future Research Directions

Technical Challenges in Implementation

Despite promising results, current DNA blood tests face several technical limitations. Understanding these challenges is essential for realistic expectations about technology implementation.

Small sample sizes represent the most significant limitation in initial studies. While results are promising, larger populations must validate these findings before widespread clinical adoption becomes feasible.

Technical challenges with degraded, aged blood samples also present obstacles. Blood samples stored for extended periods may have compromised DNA quality, affecting tumor DNA detection sensitivity.

Sample preservation techniques require improvement to maximize sensitivity. Current storage methods may not optimal for maintaining circulating tumor DNA integrity over long periods.

Additional technical limitations include:

  • Variable DNA fragment sizes
  • Contamination risks during processing
  • Equipment standardization needs
  • Quality control requirements
  • Inter-laboratory result variation

Validation Requirements

The scientific community emphasizes the need for comprehensive validation before clinical implementation. This process involves multiple phases of research and testing.

Larger population validation studies are essential next steps. These studies must include diverse patient groups across different age ranges, ethnicities, and cancer risk levels.

The validation process must address several key questions:

  • Does the test perform equally across all populations?
  • What are the optimal testing intervals?
  • How should positive results guide clinical decisions?
  • What are acceptable false positive rates?
  • How does the test integrate with existing screening?

Clinical Trial Development

Investigating early intervention strategies through clinical trials is crucial. These trials will determine how to act on positive DNA blood test results.

Trial design challenges include:

  • Ethical considerations for asymptomatic patients
  • Appropriate intervention strategies
  • Long-term follow-up requirements
  • Control group considerations
  • Risk-benefit assessments

Early intervention trials must balance potential benefits with treatment risks. Treating patients based solely on molecular evidence requires careful consideration of patient outcomes.

Therapeutic Innovation

Therapeutic approaches targeting precancerous conditions represent an exciting future direction. These treatments could prevent cancer development rather than treating established tumors.

Potential therapeutic strategies include:

  • Immunotherapy for precancerous lesions
  • Targeted molecular therapies
  • Lifestyle intervention protocols
  • Chemoprevention approaches
  • Combination treatment strategies

The development of precancer elimination therapies requires understanding cancer biology at its earliest stages. Researchers must identify the best intervention points and treatment approaches.

Technology Advancement Goals

Future research aims to improve both sensitivity and specificity of liquid biopsy cancer tests. The goal is developing tests that can reliably detect even earlier stages of cancer development.

Technology improvement areas include:

  • Enhanced DNA extraction methods
  • More sensitive sequencing platforms
  • Improved bioinformatics algorithms
  • Better sample processing protocols
  • Advanced machine learning models

Researchers are working to expand the range of detectable cancer types. The ultimate goal is a single test that can screen for all major cancer types simultaneously.

Regulatory Pathway Considerations

The path to clinical approval requires careful regulatory navigation. Health authorities must evaluate test performance, clinical utility, and safety considerations.

Regulatory challenges include:

  • Establishing performance standards
  • Defining appropriate patient populations
  • Determining clinical decision protocols
  • Ensuring quality control measures
  • Addressing reimbursement considerations

The regulatory framework for early cancer detection tests continues evolving as technology advances and clinical evidence accumulates.

Cost-Effectiveness Analysis

Future research must address the cost-effectiveness of widespread DNA blood test implementation. While promising from a clinical perspective, economic considerations influence adoption decisions.

Cost factors include:

  • Test development and production expenses
  • Healthcare system implementation costs
  • Training and infrastructure requirements
  • Long-term monitoring protocols
  • Treatment cost implications

https://clinicaltrials.gov/

Unlock Hidden Potential with Automation 🔍

This breakthrough in early cancer detection shows the power of uncovering what’s hidden. Similarly, we help businesses uncover hidden efficiencies through smart automation, improving processes you didn’t even know could be better.

Schedule a Free Automation Audit

Frequently Asked Questions About Early Cancer Detection

Q: What is early cancer detection and why is it important?

A: Early cancer detection means finding cancer before you feel sick or notice symptoms. It’s like catching a problem before it becomes serious.

When doctors find cancer early, treatment works much better. Most cancers caught early can be cured completely. The earlier cancer is found, the easier it is to treat and the better chance you have of getting completely well.

Early detection also means less harsh treatment. You might need smaller surgeries or gentler medicines instead of major operations or strong chemotherapy.

Q: How do DNA blood tests work in detecting cancer?

A: DNA blood tests look for tiny pieces of cancer DNA floating in your blood. Cancer cells constantly shed small DNA fragments into your bloodstream, creating detectable cancer biomarkers.

The test uses two main methods. Whole-genome sequencing reads your entire genetic code to find cancer-specific changes. Cell-free DNA fragmentomics uses computer programs to spot patterns that show cancer DNA is present.

These liquid biopsy cancer tests can find circulating tumor DNA even when amounts are very small. The technology is so sensitive it can detect cancer DNA among millions of normal DNA pieces.

Q: How accurate are current DNA blood tests for cancer detection?

A: Current tests show very good accuracy rates. They correctly identify cancer 87.4% of the time when cancer is present. They also correctly show no cancer 97.8% of the time when cancer is not present.

This means if you have cancer, the test will probably find it. If you don’t have cancer, the test will almost certainly show normal results. However, no test is perfect, and doctors always consider test results alongside other information.

The accuracy continues improving as technology advances and researchers refine testing methods.

Q: How far in advance can these tests detect cancer?

A: Research shows that tumor DNA detection can identify cancer up to three years before traditional methods find tumors. This gives doctors a huge head start on treatment planning.

The early cancer diagnosis window depends on cancer type and individual factors. Some cancers shed more DNA earlier than others. Personal factors like overall health and cancer genetics also influence detection timing.

This early warning system allows for much better treatment planning and potentially prevents cancer from spreading to other body parts.

Q: What types of cancer can DNA blood tests detect?

A: These tests can screen for multiple cancer types simultaneously. Current research includes lung, breast, colorectal, pancreatic, ovarian, liver, and stomach cancers.

Multi-cancer early detection represents a major advantage over traditional screening. Instead of separate tests for each cancer type, one blood draw can check for many different cancers.

Researchers continue expanding the list of detectable cancers. The goal is eventually screening for all major cancer types with a single test.

Q: What are the current limitations of DNA blood tests?

A: The main limitations include small study sizes and technical challenges with older blood samples. Scientists need larger studies with more diverse patient groups to confirm these promising results.

Blood sample storage and processing methods need improvement. Older samples may have degraded DNA that affects tumor DNA detection accuracy.

The tests also need better standardization across different laboratories to ensure consistent results regardless of where testing occurs.

Q: Are DNA blood tests available to patients now?

A: Some early versions are available, but most are still being studied. The most promising tests are in clinical trials or research studies.

Your doctor can tell you about available options in your area. Some tests may be available through research participation or specialized cancer centers.

Widespread availability will depend on completing larger validation studies and getting regulatory approval from health authorities.

Q: How often should someone get a DNA blood test for cancer screening?

A: Scientists are still determining optimal testing schedules. This will likely depend on your age, family history, and other cancer risk factors.

High-risk individuals might need more frequent testing than average-risk people. Your doctor will consider your personal risk factors when recommending a testing schedule.

As research progresses, guidelines will develop for different patient groups and risk levels.

Q: What happens if a DNA blood test shows signs of cancer?

A: A positive test means doctors found cancer DNA in your blood. However, this doesn’t automatically mean you need immediate treatment.

Your doctor will order additional tests to learn more. This might include imaging scans, biopsies, or other diagnostic procedures to find where the cancer is located and how advanced it might be.

The early detection allows for careful monitoring and planning rather than emergency treatment. You’ll work with your medical team to develop the best approach for your situation.

Q: Will insurance cover DNA blood tests for cancer screening?

A: Insurance coverage varies and continues evolving as these tests become more established. Some insurance plans may cover testing for high-risk patients.

Coverage decisions often depend on medical necessity and test approval status. Tests approved by regulatory authorities are more likely to receive coverage.

Check with your insurance provider about current coverage policies. Coverage will likely expand as tests prove their clinical value and receive broader regulatory approval.

Conclusion: The Future of Cancer Care

Early cancer detection through DNA blood tests represents a revolutionary advancement in medical technology. These liquid biopsy cancer methods offer unprecedented opportunities to identify tumors years before traditional screening methods.

The research findings demonstrate remarkable potential. Circulating tumor DNA detection can identify cancer-specific mutations up to three years before clinical diagnosis. This extended detection window creates opportunities for intervention that could fundamentally change patient outcomes.

Technology continues advancing rapidly. Whole-genome sequencing and cell-free DNA fragmentomics provide increasingly sensitive detection capabilities. These tumor DNA detection methods achieve impressive accuracy rates while maintaining low false positive rates.

The integration of advanced cancer screening technologies with routine healthcare promises to transform oncology practice. Rather than treating established cancers, healthcare providers could prevent cancer development through early intervention strategies.

Scientific collaboration drives continued progress. Researchers worldwide are working to overcome current limitations and expand testing capabilities. Larger validation studies and clinical trials will determine optimal implementation strategies.

Business leaders can learn valuable lessons from this medical breakthrough. Just as early cancer detection enables proactive healthcare, business automation allows companies to address inefficiencies before they impact operations.

The future of cancer care lies in prevention rather than treatment. DNA blood tests provide the molecular-level insight needed to identify problems before they become serious. This paradigm shift from reactive to proactive care could save millions of lives.

Healthcare systems worldwide are preparing for this transformation. The integration of early cancer detection technology requires careful planning, training, and infrastructure development.

The collaboration between scientific innovation and practical implementation mirrors successful business transformation strategies. Organizations that embrace proactive approaches to problem-solving achieve better outcomes than those that wait for problems to become apparent.

Follow developments in early cancer detection technology as research progresses. The implications extend far beyond healthcare to demonstrate the power of identifying and addressing challenges before they become critical problems.

Additional Links

Flowgrammer.ca – 💡 Unlock AI-Powered Automation! Let flowgrammer.ca handle complex workflows so you can focus on growing your business.

Episode transcript

Read the full transcript

Craig: revolutionary dna blood tests are transforming how we approach cancer screenings. these innovative liquid biopsy cancer techniques can detect microscopic traces of tumor activity years before traditional methods. at the heart of this breakthrough lies circulating tumor dna. these are tiny fragments of dna shed by tumor cells into the bloodstream. advanced testing methods can identify these fragments as cancer biomarkers providing early warning signs of disease development. this technological advancement promises to change cancer care forever. early detection could mean difference between simple treatment and complex battle for survival. this is very interesting. john, tell us more about what's going on here.

Jon: yeah. so, this is really interesting. so they've shown that cancer leaves genetic traces in the blood long before traditional diagnostics would spot a tumor, which is crazy. and it does make sense because cancer grows. right? it starts at one point and just grows. so they use blood samples, which were collected decades ago from participants in a long term health study. they analyze cases where individuals later develop cancer. with this new cutting edge genome sequencing, so, again, we couldn't have done it with old technology. we need new technology. they were able to identify specific dna mutations, which they termed circulating tumor dna or ctdna. and they were able to detect it sometimes more than three years before any clinical diagnosis, which is awesome. i think cancer is something that i feel could have been solved already, and it's just been delayed. and, this is great. this is gonna help with detection so that pharma can keep making their money on the drugs, but, this is gonna help with people who can, potentially, better chance of survival. so the thing with this is they faced a sensitivity challenge because newly formed tumors are tiny, and they only released a minuscule amount of what they're calling ctdna, which made the detection extremely difficult. so think about it looking for a needle in a haystack. right? so, by using, these advanced sequencing techniques, one out of twenty six individuals who are later diagnosed with cancer, the ctdna was detected in eight, in eight of them at the time of the blood sampling. and four had cancer dna signatures in their blood more than three years before diagnosis. this is crazy. again, we're using newer technology, though. right? so, which makes sense for an advancement like this. what are your thoughts?

Craig: this is very cool. so, this does whole genomic sequencing, revealing cancer mutations at extremely low concentrations, like you mentioned, in preserved blood samples. fragmatomics use machine learning to decode specific dna fragmentation patterns for early detection. the multimodal liquid biopsy improves accuracy by combining sequencing and the fragmentomics for stronger detection. the circular, tumor dna that you mentioned, the ctdna, serves as a reliable biomarker for multi, cancer early screenings and monitoring. current tests show 87.4% sensitivity and a 97.8 specificity nearing clinical viability standards. this also means a single blood draw could screen for multiple cancers rather than right now, you need to have one for each screening test. it's interesting that machine learning is behind a lot of this to, help identify and detect subtle dna patterns. so this is really getting down to, the future of personalized medicine.

Jon: yeah. it is. and, there was another article we we won't talk about. they were using mrna to, to code your cells to attack cancer cells. so that's something different. but there's just speaking to advancements in cancer, treatment. right? the one caveat here is that, not all cancers shed detectable amounts of ctdna at the same rate. so that could limit the effectiveness of these tests for certain types of cancer. so the results from this, from this case study was highly controlled and may not fully translate to population wide screening. so, obviously, there's gonna have to be ongoing large scale trials, to assess this impact. but, the types of cancer that the study included were breast, colon, liver, lung, pancreas, and rectal, which shed different amounts of c tdna. so i love this. i love where they're going with this. this seems like it's a viable, detection methodology based on what i read, but, again, i'm not an expert. i'm not an oncologist. so what do you think, craig?

Craig: yeah. i love this because, you know, one thing maybe we touched on, but didn't really. early cancer detection increases survival chances dramatically and minimizes the treatment complexity and invasiveness. so the earlier you can detect it, the better your odds of beating it and the less drastic the treatment has to be. right. so if we can now detect even eighty percent of cancers three years beforehand, that means significant, quality of life for people who, are suffering from this, from cancer. they get it, get it detected, and hopefully get treatment that's much lighter and easier and get it resolved within a very short period of time rather than, you know, the extensive chemo and stuff that people have when your testing comes too late. so i love this. it's yeah. i understand that it's a caveat. i understand also that this will probably be expensive, so it's gonna take a while to get the price down because we are talking about personalized medicine. it's your dna. we're scanning your for defects and stuff, and it's specific to you. so there's things that have to happen there. but, i love where this is heading. every time we see when they apply ai to medicine or to science and whatnot, we're starting to see major breakthroughs, and they're coming faster and faster, and it's great to see.

Jon: when they apply it properly with people that know what they're doing as opposed to just trying to use an ai and getting hallucinations and crap. so

Craig: yeah. we're not talking about somebody typing into gtp writing me a school paper. we're talking about comp finding new proteins, comparing, finding medicines that don't interact negatively to each other. yeah. all and this kind of stuff where we're, that has to be used properly. the clinical testing has to be done, but it's interesting to see that we're we are making gigantic leaps forward in science as a result of this.

Jon: yeah. this is cool. yep.

Craig: so we'll have to see how long is this gonna take till we're gonna see it live. do you know?

Jon: no clue. i'm guessing maybe three to five years.

Craig: yeah. i'm looking through my notes here. i didn't see anything in here. no. i didn't make any notes on the date, so i guess i didn't see anything in the article. so i'd love to see this. you know, we all know people who have had cancer and affected this in our life, and it'll be great to see if, as a society, we can get it and treat this early and maybe not put an end to it, but significantly reduce the amount of people who have to go into long term care or deep chemo as a result of getting cancer. so let's hope this progresses fast. yeah. we'd love to hear feedback on this new cancer, detection, and, love to hear your thoughts. leave your comments below.

More from Silicon Scoop

All episodes